An Expanded Genetic Information System

描述（由申请人提供）：DNA字母表不限于 四个标准核苷酸。相反，12个核碱基形成6个碱基对 通过相互排斥的氢键结合的模式是可能的， 沃森-克里克碱基对的几何结构。这是一个扩展的基因 信息系统（Aegis），一个新的，“基于规则”的分子识别系统 其携带蛋白质功能性，可以以组合形式制备， 可以像核酸一样被复制。鉴于对这一点的丰富理解， 经过十年的研究，在本纳实验室，宙斯盾系统是一个 技术转让机会。在第一阶段研究中， 实验验证了Aegis提供一组正交， 可用于支持高度多路复用（100或更多）的非交叉反应标签 分析物）DNA诊断系统。这些研究包括溶液和 固相，与Luminex仪器支持多路复用，并与 聚合酶在第二阶段，我们将制备1000个独立结合的DNA样 标签，进一步开发支持个体患者基因分型的工具，以及 选择既掺入官能化核苷酸又掺入 将Aegis组分转化为寡核苷酸。 拟定商业应用： 支持“基于规则的分子识别”的化学系统具有广泛的商业应用性，包括未来的“蓝天”（例如纳米技术和分子计算）。 更直接的是，Aegis系统正在支持一个商业诊断系统，并在第一阶段导致了一个检测单核苷酸多态性（SNP）的分析。 这种检测方法有望在预测医学和个性化护理方面带来革命，具有潜在的市场价值。

DESCRIPTION (provided by applicant): The DNA alphabet is not limited to the four standard nucleotides. Rather, twelve nucleobases forming six base pairs joined by mutually exclusive hydrogen bonding patterns are possible within the geometry of the Watson-Crick base pair. These form An Expanded Genetic Information System (Aegis), a new, "rule based" molecular recognition system that carries protein functionality, can be prepared in combinatorial form, and can be copied much like nucleic acids. Given the rich understanding of this system after a decade of research in the Benner laboratory, Aegis is a technology transfer opportunity. In the Phase I study, a comprehensive set of experiments validated the ability of Aegis to provide a set of orthogonal, non-cross reacting tags useful to support highly multiplexed (100 or more analytes) DNA diagnostics systems. These included studies in both solution and solid phase, with the Luminex instruments that support multiplexing, and with polymerases. In Phase II, we will prepare 1000 independently binding DNA-like tags, further develop tools to support genotyping of individual patients, and select for polymerases that incorporate both functionalized nucleotides and Aegis components into oligonucleotides. PROPOSED COMMERCIAL APPLICATION: Chemical systems that support "rule based molecular recognition" have wide commercial applicability, including in come "blue skies" (nanotechnology and molecular computing, for example). More immediately, the Aegis system here is supporting a commercial diagnostics system, and has led in the Phase I period to an assay that detects single nucleotide polymorphisms (SNPs). Such assays promise a revolution in predictive medicine and personalized care, with potential market value.